 Home > Active Ingredient News > Antitumor Therapy > 2023CASH| Pediatrics, Big Blood, Big Health: Parallel to the World Frontier to Cultivate Chinese Children's Hematology

2023CASH| Pediatrics, Big Blood, Big Health: Parallel to the World Frontier to Cultivate Chinese Children's Hematology

 Last Update: 2023-02-02
 Source: Internet
 Author: User

Tags

health behavior change

what all elements

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The report of the 20th National Congress of the Communist Party of China proposed to "put the protection of people's health in a strategic position of priority development and improve the people's health promotion policy"
.
Children are the future of the motherland, and the sustained and rapid development of pediatric hematology is an indispensable part of
this strategic task.
On the afternoon of January 7th, the 3rd Chinese Conference on the Development of Hematology in Children and Hematology was successfully held
.
This forum focused on the latest research progress and development direction of precision diagnosis and treatment of pediatric hematology, and invited top experts in pediatric hematology at home and abroad to jointly create the first academic event
in the field of pediatric hematology.

Professor Wang Tianyou, Director of the Chinese Medical Association and Chairman of the Pediatrics Branch of the Chinese Medical Association, Professor Liu Yufeng, Head of the Hematology Group of the Pediatric Branch of the Chinese Medical Association, Director of the Institute of Pediatric Hematology and Oncology of Zhengzhou University, and Professor Zhu Xiaofan, Director of the Pediatric Hematology Diagnosis and Treatment Center of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) served as the chairs
of the forum.

Professor Wang Tianyou pointed out in his speech that to achieve children's health can achieve the health of Chinese people, this forum closely around the theme of "big blood, big health", for the development of children's blood diseases to provide a good communication platform, hope that everyone in the understanding of the progress of children's blood diseases research at home and abroad, can contribute new wisdom
to the prevention and treatment of children's blood diseases in China 。 In his speech, Professor Liu Yufeng first affirmed the contribution made by the team of the Pediatric Hematology Diagnosis and Treatment Center of the Hematology Hospital of the Chinese Academy of Medical Sciences in the field for more than ten years, and hoped that the leading team of pediatric hematology in China can continue to play a leading role, further improve the overall research level of pediatric hematology diagnosis and treatment in China, and benefit more pediatric hematology patients
.

CASH

Pay attention to children's health

Leading the new trend of research in the field of children's blood

Professor Zhang Ting, Deputy Director of Capital Institute of Pediatrics, gave a lecture
on the theme of "Progress in Children's Epigenetics and Child Development and Health".
Professor Zhang Ting proposed that nutrition and exercise are the basic elements that determine the trajectory of children's development, and early dietary nutrition and scientific and reasonable exercise can have a "lifelong" impact
on children's development through epigenetic mechanisms.
Pediatricians should advocate that children pay equal attention to diet balance and exercise in disease recovery, which is of great significance
to avoid the occurrence of improper developmental trajectories in children.

CASH

Individualized clinical protocols combined with translational medicine research

Directly address the refractory/recurrent pain points of childhood acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and although the optimization of chemotherapy regimens has made great strides in the efficacy of ALL in children, there has been little
improvement in the prognosis of refractory/recurrent ALL in children.
Professor Deepa Bhojwani of Children's Hospital of Los Angeles led the latest progress and challenges
of immunotherapy for refractory/recurrent ALL in children with the theme of "How to Improve the Prognosis of Refractory/Recurrent ALL in Children".
In addition to the clinical diagnosis and treatment plan of precision chemotherapy, promoting the clinical translation of basic research results is an effective means to
further optimize the treatment plan of pediatric ALL and improve the prognosis of children 。 Professor Zhang Yingchi, Hospital of Hematology, Chinese Academy of Medical Sciences, pointed out that single-cell sequencing technology is powerful in exploring cell heterogeneity and other aspects with the theme of "Application of Single Cell Sequencing Technology in Children's ALL Research", and that single-cell transcriptome sequencing is widely used in the research fields of the occurrence mechanism of B-ALL minimal residual disease in children, the cloning evolution of recurrent resistant T-ALL, the heterogeneity and recurrence mechanism of ALL in children, and the dynamic changes of HSPCs before and after B-ALL chemotherapy.
It is believed that there will be more new programs to benefit
more children.

CASH

The precise risk stratified model combined with individualized hematopoietic stem cell transplantation program improved the prognosis of children with acute myeloid leukemia

Acute myeloid leukemia (AML) is a very heterogeneous malignancy with wide variation in efficacy
.
In this lecture, Dr.
Ruan Min from the Hematology Hospital of the Chinese Academy of Medical Sciences gave a lecture on the precision diagnosis and treatment of AML in children, explained and compared in detail the diagnosis and classification criteria of AML diseases in the 2022 version of the WHO standard and the 2022 International Consensus Classification (ICC), and introduced the treatment plan, new drug application and supportive treatment of AML.
Based on the clinical data of more than 700 cases of AML at home and abroad, the accurate risk stratified prognosis assessment model of AML for children was introduced, and it was hoped that the clinical application of this model could better improve the prognosis
of AML in children.
Professor Wang Yu of Peking University People's Hospital shared the research results of "allogeneic hematopoietic stem cell transplantation of pediatric myeloid tumors" and the application of new therapies in pediatric AML against the background of the rapid increase in the number of
transplantation cases in children with AML in China, combined with years of valuable clinical experience.
She emphasized that the concept of precise stratification should run through the whole process of transplantation, and the treatment methods should take the transplantation platform as the core, combined with various new drugs and new cell therapies, and continuously improve the efficacy
of children with a development vision.

CASH

Interpretation of international experts

New guidelines and standards for diseases of bone marrow failure in children

In view of the newly released WHO classification and standards for myeloid tumors in 2022, this forum invited international experts to share the application of
new guidelines in pediatric hematological diseases 。 Professor Mark Fleming of Boston Children's Hospital of Harvard University gave a lecture on the theme of "Myelodysplastic Diseases and Myelodysplastic Syndromes in Children: Morphology and Classification", clarified the diagnostic basis and classification criteria of the 2022 WHO MDS in children and the concept and significance of germline susceptibility syndrome, emphasized the diagnostic difficulties of MDS diseases in children and the clinical significance of distinguishing MDS from BMF, and analyzed the morphological characteristics of bone marrow in some BMF diseases through intuitive bone marrow morphological smears
。 For rare childhood bone marrow failure diseases, Professor Marcin W.
Wlodarski of St.
Jude Children's Hospital, organizer of the International Conference on Congenital Pure Red Cell Aplastic Anemia (DBA) and leader of the new international consensus on DBA, introduced the new version of the international expert consensus to be published, pointing out that in the new consensus, DBA was renamed DBA syndrome, and the diagnostic criteria were greatly modified.
More attention is paid to the monitoring and dose adjustment of adverse reactions in DBA patients taking hormones for a long time and the evaluation and treatment of iron overload in transfusion-dependent patients, and the long-term monitoring and management of DBA hematopoietic stem cell transplantation are
also detailed.

CASH

Parallel to the forefront of the world

Keep abreast of international trends in the development of childhood blood diseases

Professor Zhu Xiaofan of the Hematology Hospital of the Chinese Academy of Medical Sciences took stock of the key contents related to pediatric hematology at the 2022 ASH Annual Meeting, including the research results of the Pediatric Hematology Center team on the single-cell transcriptome and proteome of children's severe aplastic anemia (SAA), which provided further research directions
for the targeted therapy of SAA 。 She said that ASH in 2022 reflects the development trend of the international field of pediatric hematology, especially the development of single-cell sequencing, new drug research and new treatment methods, which provides new possibilities for improving the diagnosis and treatment of pediatric hematology, and hopes to see more achievements of domestic teams in international exchanges in the future and voice more Chinese voices
in the field.

As the opening academic conference in this field, this sub-forum on pediatric hematology closely focuses on the theme of "big blood, big hygiene, big health", and accurately focuses on the breakthroughs in the diagnosis and treatment of various benign and malignant hematological diseases in children, which provides new ideas and brings new hope
for the future development of children's hematology diseases and children.
It is believed that in the new year, with the joint efforts of many colleagues in the field of pediatric hematology, the diagnosis and treatment level of pediatric hematology in China will reach a new level, so that more children with hematological diseases will benefit
.

Source: Institute of Hematology, Hematology Hospital